Schifano F, Garbin A, Renesto V, De Dominicis M G, Trinciarelli G, Silvestri A, Magni G
Department of Psychiatry, University of Padua, School of Medicine, Italy.
Acta Psychiatr Scand. 1990 Mar;81(3):289-94. doi: 10.1111/j.1600-0447.1990.tb06499.x.
A double-blind, randomized 4-week mianserin vs maprotiline trial was conducted in 48 depressed geriatric medical inpatients. The drug dosages were up to 90 mg of mianserin and up to 150 mg of maprotiline per day. Efficacy was measured by the Geriatric Depression Scale, the Hopkins Symptom Check List depression subscale and the Clinical Global Impression Scale. The overall dropout figure was 27% of the sample. Side effects were relatively similar in the two treatment groups and suggested a safety profile somewhat better than that of the first-generation antidepressants. Mianserin showed some advantages in efficacy over maprotiline, particularly by the 4th week of the trial, but the overall figures of treatment responders were rather small (Geriatric Depression Scale: mianserin 48%, maprotiline 30%). Clinical trials vs placebo are needed to clarify the role of antidepressant pharmacotherapy in depressed geriatric medical inpatients.
对48名老年内科住院抑郁症患者进行了一项为期4周的米安色林与马普替林双盲随机试验。药物剂量为米安色林每日最高90毫克，马普替林每日最高150毫克。通过老年抑郁量表、霍普金斯症状清单抑郁分量表和临床总体印象量表来衡量疗效。样本的总体脱落率为27%。两个治疗组的副作用相对相似，表明安全性略优于第一代抗抑郁药。米安色林在疗效上比马普替林有一些优势，尤其是在试验的第4周，但治疗有效者的总体数字相当小（老年抑郁量表：米安色林48%，马普替林30%）。需要进行与安慰剂对照的临床试验，以明确抗抑郁药物治疗在老年内科住院抑郁症患者中的作用。
